Tivorbex is a drug owned by Genus Lifesciences Inc. It is protected by 3 US drug patents filed from 2014 to 2015 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 23, 2030. Details of Tivorbex's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9089471 | Formulation of indomethacin |
Apr, 2030
(4 years from now) | Active |
| US8734847 | Formulation of indomethacin |
Apr, 2030
(4 years from now) | Active |
| US8992982 | Formulation of indomethacin |
Apr, 2030
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Tivorbex's patents.
Latest Legal Activities on Tivorbex's Patents
Given below is the list of recent legal activities going on the following patents of Tivorbex.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| 7.5 yr surcharge - late pmt w/in 6 mo, Small Entity | 07 Feb, 2023 | US9089471 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 Feb, 2023 | US9089471 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 06 Feb, 2023 | US9089471 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 30 Sep, 2022 | US8992982 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 01 Dec, 2021 | US8734847 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jan, 2019 | US9089471 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 Oct, 2018 | US8992982 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 27 Nov, 2017 | US8734847 |
| Application ready for PDX access by participating foreign offices
Critical | 31 Aug, 2015 | US8992982 |
| Application ready for PDX access by participating foreign offices
Critical | 31 Aug, 2015 | US9089471 |
FDA has granted several exclusivities to Tivorbex. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Tivorbex, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Tivorbex.
Exclusivity Information
Tivorbex holds 1 exclusivities. All of its exclusivities have expired in 2017. Details of Tivorbex's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 24, 2017 |
US patents provide insights into the exclusivity only within the United States, but
Tivorbex is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Tivorbex's family patents as well as insights into
ongoing legal events
on those patents.
Tivorbex's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tivorbex's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 23, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tivorbex Generic API suppliers:
Indomethacin is the generic name for the brand Tivorbex. 34 different companies have already filed for the generic of Tivorbex, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tivorbex's generic
Alternative Brands for Tivorbex
Tivorbex which is used for relieving pain., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Btcp Pharma |
| |||
| Fresenius Kabi Usa |
| |||
| Recro Gainesville |
| |||
| Tersera |
| |||
| Upjohn |
| |||
| Zyla |
| |||
About Tivorbex
Tivorbex is a drug owned by Genus Lifesciences Inc. It is used for relieving pain. Tivorbex uses Indomethacin as an active ingredient. Tivorbex was launched by Genus in 2014.
Approval Date:
Tivorbex was approved by FDA for market use on 24 February, 2014.
Active Ingredient:
Tivorbex uses Indomethacin as the active ingredient. Check out other Drugs and Companies using Indomethacin ingredient
Treatment:
Tivorbex is used for relieving pain.
Dosage:
Tivorbex is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG | CAPSULE | Discontinued | ORAL |
| 40MG | CAPSULE | Discontinued | ORAL |